Baricitinib in the Management of Coexisting Alopecia Areata and Atopic Dermatitis: A Case Report

Introduction Alopecia areata (AA) is an autoimmune disorder causing transient, non-scarring hair loss [1]. Recent advances have introduced promising treatments, including Baricitinib, a Janus kinase (JAK) inhibitor, which has shown significant effectiveness in treating autoimmune and inflammatory conditions, such as AA and atopic dermatitis (AD) [2]. Case Presentation A 22-year-old female with congenital AD and AA since 2019, presented with a AD-related rash, irregular heavy menstrual periods, and patchy hair loss. She received cyclosporine therapy (2022–2023) with limited efficacy, leading to the initiation of Dupilumab in 2023. However, Dupilumab was discontinued after one year due to heavy uterine bleeding, which could not be definitively linked to the medication. Following discontinuation, both AD and AA worsened, presenting with multiple hair loss patches and xerotic, erythematous, scaly plaques symmetrically distributed across flexural regions and posterior thighs. The SCORAD index was 59.1, and the DLQI score was 15, reflecting significant quality-of-life impairment. Given the coexistence of AD and AA and their substantial impact, Baricitinib was prescribed. The patient experienced marked clinical improvement, with complete resolution of AD-associated rashes and significant hair regrowth, leading to the full resolution of AA-related bald patches. Discussion AA affects 1–2% of the population, with a lifetime risk of 1.7% [3]. Research links AD to a higher risk of autoimmune conditions like AA, with a study showing increased autoimmune disease prevalence in AD patients (5.8%) compared to healthy controls (4.3%) and a significant association between AD and AA (aHR: 1.33; 95% CI: 1.07–1.64) [4]. The JAK-STAT pathway plays a key role in AA pathogenesis, supporting the efficacy of JAK inhibitors [5]. Baricitinib, an oral JAK-1/2 inhibitor, blocks pro-inflammatory cytokines and immune pathways relevant to both AD and AA, providing a targeted and effective therapeutic option [2,5,6]. Conclusions Baricitinib represents a promising treatment for patients with coexisting AA and AD by targeting shared immune pathways. This case highlights its ability to reduce inflammation, promote significant hair regrowth, and improve overall quality of life.